Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis: a network meta-analysis of phase 3–4 randomized trials

Puntos clave

• The aim is to compare the efficacy of different targeted systemic therapies for moderate-to-severe atopic dermatitis.
• Conducted a network meta-analysis of phase 3-4 randomized trials
• Compared the efficacy outcomes of approved targeted therapies
• Evaluated upadacitinib's performance relative to other therapies
• Upadacitinib 30 mg once daily ranked highest in efficacy outcomes
• Findings are based on indirect comparisons
• Need for head-to-head trials for confirmation of effectiveness